Tech Company Financing Transactions

Carbylan Therapeutics Funding Round

On 11/26/2007, Carbylan Therapeutics raised $20 million in Series B funding from Vivo Capital, Alta Partners and InterWest Partners.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B

Vivo Capital (Lead Investor) (Albert Cha)

Alta Partners

InterWest Partners

Proceeds Purpose
Proceeds from this round of financing will be used to advance Carbylan's lead product candidates based on chemically engineered polymers of hyaluronic acid. Carbylan's proprietary technology allows delivery of biomaterial-based medical devices as injectable liquids that self-polymerize, covalently bind to tissues at the target delivery site and, when combined with appropriate therapeutic agents, uniquely enable controlled drug release. The Company currently is conducting post-approval clinical studies for its first product AdvaCoat™ Sinus Dressing, and a second generation device/drug combination product AdvaCoat™ Rx for chronic rhinosinusitis will enter the clinic early next year. The company's second product, ActaVisc™ - viscosupplement for intra-articular injection - will also enter the clinic early next year as a treatment for osteoarthritis.

Company Information

Company Status
Medical Devices & Instruments
Mailing Address
3181 Porter Dr.
Palo Alto, CA 94304
Email Address
Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products
Carbylan Therapeutics LinkedIn Company Profile
Social Media
Carbylan Therapeutics Company Twitter Account
Company News
Carbylan Therapeutics News
Carbylan Therapeutics on Facebook
Carbylan Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
David Renzi
  David Renzi LinkedIn Profile  David Renzi Twitter Account  David Renzi News  David Renzi on Facebook
Chief Financial Officer
Michael White
  Michael White LinkedIn Profile  Michael White Twitter Account  Michael White News  Michael White on Facebook
VP - R & D
David Gravett
  David Gravett LinkedIn Profile  David Gravett Twitter Account  David Gravett News  David Gravett on Facebook
VP - Regulatory Affairs
Hayley Lewis
  Hayley Lewis LinkedIn Profile  Hayley Lewis Twitter Account  Hayley Lewis News  Hayley Lewis on Facebook



Browse more venture capital transactions:

Prev: 11/26/2007: Achievers venture capital transaction
Next: 11/26/2007: Ceptaris Therapeutics venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary